<DOC>
	<DOC>NCT00928889</DOC>
	<brief_summary>This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.</brief_summary>
	<brief_title>Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<criteria>Newly diagnosed type 2 diabetes mellitus patients HbA1c &gt; 6.5 and &lt; 9.0% Fasting fingertip capillary blood glucose (FCBG) &lt; 9 mmol/L after 2 weeks diet control History of acute metabolic complications in the past 3 months or of severe diabetic complications or severe infections or active substance abuse Liver disease Patients under oral hypoglycemic drugs and/or insulin treatment, or corticosteroid treatment within past 4 weeks Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>diabetes mellitus, type 2</keyword>
	<keyword>nateglinide</keyword>
	<keyword>acarbose</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>dyslipidemias</keyword>
	<keyword>C-reactive protein</keyword>
</DOC>